Researchers
Our research is structured into research themes, programs of work and teams. We are committed to collaboration and to work together.
Research theme leaders
BA (Education) PhD Candidate
Director of First Nations Strategy and Leadership; Head, First Nations Health and Equity Research
BSc PhD
Head, Chronic Diseases Research
OAM BSc (Hons) GradDipClinEpi PhD
BSc (Hons) PhD
Theme Head, Wellbeing and Mental Health
BSc (Hons) MSc PhD
Feilman Fellow; Head, Precision Health Research and Head, Translational Intelligence
BMedSci (hons), PhD
Shaping excellence
Rewarding excellence
Learn more about how The Kids rewards research excellence
Learn more about how The Kids rewards research excellenceResearch governance
We pride ourselves on conducting research to the highest standards possible
Find out more about research governanceCurrent career opportunities
Want to join our team and help make a difference to child health?
Learn more about Current career opportunitiesHelp shape our research
Find out how you can involve consumers and the community in your research
Help shape our researchReports & findings
Model-informed precision dosing of vancomycin in children 3 months to 18 years of age using Australia-wide data
Vancomycin is used to treat serious gram-positive infections in children; however, effective dosing information for those aged 3 months to 18 years is limited. We aimed to determine an optimized dosing strategy for this age group.
Enhancing a diverse population: the American Thoracic Society Mentoring Program for Underrepresented in Medicine
Speech and language therapists’ training and service delivery with children and adults with neurogenic communication disorders from culturally and linguistically diverse backgrounds
Speech and language therapists' (SLT) practice with cultural and linguistic diverse (CALD) populations with acquired and congenital neurogenic communication disorders in Denmark and Sweden is becoming more urgent due to demographic changes.
Regulating the Irregular: Phage Therapy and the Case for a Regulatory Sandbox Approach in Australia
Bacteriophages (phages) are viruses that selectively kill bacteria and offer a promising option to address the growing global pandemic of antimicrobial-resistant infections. However, phage therapy does not easily align with traditional regulatory pathways designed for fixed-composition chemical drugs or biologics with fixed non-evolving compositions.